Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.45 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990151 | 0.98 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2CCR1PRKAB2 | |
| SCHEMBL3628532 | 0.96 | SLC6A3 (0.53) | SLC6A3SLC6A4SLC6A2CCR1PRKAB2 | |
| SCHEMBL17186769 | 0.92 | SLC6A3 (0.51) | SLC6A3SLC6A4SLC6A2CCR1PRKAB2 | |
| SCHEMBL17186931 | 0.84 | SLC6A3 (0.45) | SLC6A3SLC6A4SLC6A2CCR1PRKAB2 | |
| SCHEMBL2274203 | 0.84 | DRD2 (0.59) | SLC6A3SLC6A4SLC6A2CCR1PRKAB2 | |
| SCHEMBL17186726 | 0.82 | CCR1 (0.50) | SLC6A3SLC6A4SLC6A2CCR1OPRL1 | |
| SCHEMBL15277102 | 0.81 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2PRKAB2PRKAG1 | |
| SCHEMBL13971131 | 0.81 | SLC6A4 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17186722 | 0.80 | SLC6A3 (0.44) | SLC6A3SLC6A4SLC6A2CCR1PRKAB2 | |
| SCHEMBL17186929 | 0.79 | SLC6A3 (0.49) | SLC6A3SLC6A4SLC6A2PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| EP-3131880-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015159233-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-10-22 | — | — | WO | disclosed |
| US-8901152-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8242139-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2452937-A1 | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme | Abbott Laboratories (US) | 2012-05-16 | — | — | EP | disclosed |
| CN-101743234-A | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LAB | 2010-06-16 | — | — | CN | disclosed |
| EP-2142521-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080312282-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2008134693-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | SLC6A3 4602/4885SLC6A4 4792/4885SLC6A2 4739/4885 |
| US-20080312282-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | DGAT1, DGAT2, LCAT | SLC6A3 1550/4885SLC6A4 3093/4885SLC6A2 2442/4885 |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | SLC6A3 1550/4885SLC6A4 3093/4885SLC6A2 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.